Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Taiwan / NCT07159399
Enrolling by invitation Not applicable

A Pharmacist-Led Education Program to Improve Adherence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation

NCT07159399 · tracked via the Priya Life Science Taiwan tracker
Sponsor
National Taiwan University
Phase
Not applicable
Started
2025-03-05
Last updated
2025-09-08

Condition(s) studied

Atrial Fibrillation (AF)

Investigational drug(s) / intervention(s)

Pharmacist-led patient educationUsual Care

Pharmacist-led patient education: Trained pharnacists will provide information on: (1) the indication and the reason of DOAC prescription, (2) the name and the appearance of the DOAC agent, (3) the dose, frequency, time of administration, (4) the mechanism of action, (5) management of missed doses, (6) potential side effects and self-monitoring, and (7) perioperative management. An education leaflet about DOACs will also be provided to improve patients' understanding about the use of DOACs.

Usual Care: Patients in the usual care group will receive only usual care, without pharmacists providing additional DOAC education materials.

Study summary

Atrial fibrillation (irregular heartbeat) increases the risk of stroke, and patients are commonly treated with direct oral anticoagulants (DOACs). However, when patients do not take these medications regularly, the drugs may not work effectively, increasing health risks.

In this study, called PharmAD-AF, specially trained pharmacists will meet with patients who have atrial fibrillation and are prescribed DOACs. They will offer personalized education and support to help patients take their medications as directed.

Researchers will compare groups of patients who receive this pharmacist-led education versus those who receive usual care. The main goals are to assess whether pharmacist support improves how consistently patients take their DOACs and how well the treatment prevents strokes while avoiding the side effects of DOAC therapy.

If successful, the study will demonstrate how pharmacist-led education can help patients stick to their treatment plan and reduce serious health risks, offering a practical way to improve heart-related care.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * 18 years of age or older * have a confirmed diagnosis of AF * are expected to begin DOAC therapy for at least 3 months for stroke prevention Exclusion Criteria: * cannot understand DOAC-related education due to low literacy, language barriers, or cognitive impairment * have been on DOAC therapy for more than 6 months * using DOACs in off-label regimens * are pregnant or breastfeeding

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
National Taiwan University Hospital Taipei Taiwan

More National Taiwan University trials in Taiwan

Ultrasonication-mediated Microbubbles Dressing for Hand Arthritis Recruiting
Effects of Elastic Band Resistance Exercise on Muscle Strength and Depression in Hospitalized Elderly. Recruiting
Thirst Translation and RCT Enrolling by invitation
Interactive Exergaming With Otago Exercise Program on Mobility in Community-Dwelling Older Adults Starting soon

Other trials for the same condition

Atrial Remodeling After PFA Substrate Modification for Persistent AF (PeAF) Starting soon
Cycle-Length Mapping in Patients With Non-paroxysmal Atrial Fibrillation Recruiting
Protocol-Driven Continuous Infusion Versus Intermittent Bolus Heparin During Atrial Fibrillation Ablation Active, not recruiting
Utility of Analyzing Atrial Signal Electrograms in Patients with Atrial Fibrillation Using Next-Generation Ensite X Software: a Prospective Study Active, not recruiting
Leveraging AI-ECG Technology for Early Notification and Tracking of AF Development Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07159399 on ClinicalTrials.gov ↗ ← All trials in Taiwan